Skip to main content
Research

Current Research

ALZHEIMER’S DISEASE RESEARCH

 

 A4: Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss

If you are a healthy older adult with normal memory, this could be the right time for you to join the fight to prevent the memory loss of Alzheimer’s disease. This study is for Healthy older individuals, 65 to 85 years of age, who have not shown signs of memory loss and are not taking medications for memory difficulties.

Interested patients will be consented to begin screening procedures such as memory assessments, physical, labs, MRI and PET scan at no cost. If qualified, participants will visit our site once per month for an infusion of the study drug. Scientists believe that AD-related damage to the brain begins many years before the symptoms of memory loss emerge.  It is hoped that starting treatment very early will help slow the progression of memory loss.
This is a Phase 3 trial.

For more information, please contact Caroline Kumm at 716-558-3492.

 

CREAD: Study of Crenezumab in Patient’s with Prodromal to Mild Alzheimer’s disease

This Phase 3 trial is looking for people ages 50-85 in the early stages of memory issues to take part in a 2 year study of an investigational drug. In this study, participants will get either Crenezumab or placebo in addition to any background therapy you may or
may not be receiving. 

Interested patients will be consented to begin screening procedures such as memory assessments, physical, labs, MRI and PET scan at no cost. If qualified, participants will visit our site once per month for an infusion of the study drug. It is hoped that, if it works, Crenezumab may slow down how fast the disease progresses. 

For more information, please contact Amanda Jamison at 716-819-4117.

 

RECOGNITION:  Study of Piromelatine in Patients with Mild Dementia Due to Alzheimer’s Disease

The purpose of this Phase 2 research study is to determine an effective dose of a once a day tablet, piromelatine, in patients with Mild AD between the ages of 60-85.

The study will take place over 7 months and include visits to our site and weekly telephone calls. The potential sleep enhancing capacities of piromelatine may also be important to the study. Recent clinical and biochemical evidence has identified an interesting link between sleep, cognitive dysfunction and Alzheimer's disease. Patients will be randomly assigned by chance to receive either piromelatine (5mg, 20mg, or 50mg) or placebo.

For more information, please contact Amanda Jamison at 716-819-4117.

BRAIN TUMOR/ONCOLOGY RESEARCH

For information regarding brain tumor and oncology research contact Rebecca Hogan, Clinical Research Coordinator, at 716-558-5670

EPILEPSY RESEARCH 

For more information, please contact Amanda Jamison at 716-819-4117.

HEADACHE/MIGRAINE RESEARCH

Chronic Migraine
If you suffer from 15-26 headache days a month and are between 18 and 65 years of age you may qualify for exciting new research using CGRP therapy. If you are interested in participating please call 716-558-5670.

Episodic Migraine
To qualify for these trials you must be 18-65 years of age and suffer from 2-14 migraine headache days per month. The trials include both prophylactic and abortive medications. If you are interested in participating please call 716-558-5670.

Cluster Headache
To qualify for these trials you must be between 18-70 years of age and have a 1 year history of cluster headache diagnosis. If you are interested in participating please call 716-558-5670.   

 

MAJOR DEPRESSIVE DISORDER RESEARCH

LVM-MD-11: Safety and Efficacy of Levomilnacipran ER (Fetzima) in Adolescent Patients With Major Depressive Disorder

The purpose of this research study is to evaluate the drug levomilnacipran extended-release for how well the drug works, the side effects, and how well tolerated compared to placebo in adolescents (12-17 years of age) with depression. 

Participation will last about 10 weeks and will include 9 visits to the study center. Patient’s will be randomly assigned study drug to compare Levomilnacipran ER 40 mg/day, Levomilnacipran ER 80 mg/day, Fluoxetine (Prozac) 20 mg/day, and placebo. All tablets will look the same.

For more information, please contact Caroline Kumm at 716-558-3492.

MÉNIÈRE’S DISEASE RESEARCH STUDY SEEKS VOLUNTEERS

More than 600,000 people in the US suffer from Ménière’s disease, a disorder of the inner ear which can affect balance and hearing. Patients may experience vertigo (a feeling that the patient’s surroundings are moving when they are not), dizziness, nausea, hearing loss, or ringing in the ears.

The Ménière’s disease research study is currently seeking female and male volunteers who are between 18 and 85, have been diagnosed with unilateral (one ear only) Ménière’s disease, and have documented hearing loss. The purpose of this research study is to evaluate the safety and effectiveness of an investigational drug.

Study participants will receive study-related exams, lab tests, and investigational study medication at no charge.

For more information and to see if you may qualify, call 888-205-5801 or visit www.OtonomyResearch.com today!

MULTIPLE SCLEROSIS RESEARCH

 

PASSAGE: Safety Study in Patients with Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

For this study, relapsing-remitting multiple sclerosis (RRMS) participants must be starting either Gilenya at time of study entry, starting another approved DMT, or have started a DMT within the past 6 months: Betaseron, Extavia, Avonex, Rebif, Copaxone, Aubagio and Tecfidera.

For more information, please contact Caroline Kumm at 716-558-3492.

PARKINSON'S DISEASE RESEARCH

Study to investigate the efficacy safety and tolerability of PF-06649751 in subjects with motor fluctuations due to Parkinson’s disease. 

Parkinson’s disease affects millions of people worldwide and there is currently no cure. If you have been diagnosed with Parkinson’s disease, you might be eligible to participate in our clinical research study. The purpose of this research study is to evaluate the safety and the effects of different doses of the investigational medication or placebo taken with Levodopa (L-Dopa) as a treatment for Parkinson’s disease.

Participant Eligibility:
• You are a male or female between the ages of 45 to 85 with Parkinson’s disease.
• You are on a daily dose of at least 400mg of L-Dopa
• You experience motor fluctuations and “wearing off”symptoms

Qualified volunteers will receive study-related medical evaluations at no cost. Compensation for time and reasonable reimbursement for travel related expenses are available.

For more information, please contact Dr. Traci Aladeen at 716-558-9918.

RESTLESS LEG SYNDROME RESEARCH

XP109: Efficacy and Safety Evaluation of HORIZANT in Adolescents Aged 13 to 17 Years Old with Moderate-to-Severe Primary Restless Legs Syndrome

HORIZANT has been studied in adults with restless legs syndrome and is approved by the Food and Drug Administration (FDA) for adults, however it has not been approved by the FDA for teenagers. 

In this study some participants receive HORIZANT and some participants receive a placebo.

For this study you will take 2 tablets of study drug daily for 12 weeks. To find out how well HORIZANT works, 2 different doses of HORIZANT (300 mg or 600 mg) will be compared to placebo, but no one will know until the study is over which study drug a study participant was taking during the study. After completion of this trial, you can continue to the Open Label study, which means all participants receive HORIZANT.

For more information, please contact Caroline Kumm at 716-558-3492.